Faculty Profiles - KANAZAWA Kenya

Papers - KANAZAWA Kenya

Division display181 - 200 of about 540／ All the affair displays >>

Clinical Outcomes of Postoperative Adjuvant Chemotherapy for Surgically Resected High-Grade Pulmonary Neuroendocrine Carcinoma.

Kotake M, Imai H, Kaira K, Endoh H, Yamada Y, Kaburagi T, Kiyoshima M, Sugiyama T, Nakamura Y, Kasai T, Matsuguma H, Minemura H, Kanazawa K, Suzuki H, Fujita A, Minato K

Chemotherapy 67 ( 3 ) 142 - 151 2022（ ISSN:0009-3157 ）

Pretreatment glasgow prognostic score predicts survival among patients administered first-line atezolizumab plus carboplatin and etoposide for small cell lung cancer.

Wasamoto S, Imai H, Tsuda T, Nagai Y, Minemura H, Yamada Y, Umeda Y, Kishikawa T, Shiono A, Kozu Y, Shiihara J, Yamaguchi O, Mouri A, Kaira K, Kanazawa K, Taniguchi H, Kaburagi T, Minato K, Kagamu H

Frontiers in oncology 12 1080729 2022（ ISSN:2234-943X ）

Pretreatment glasgow prognostic score predicts survival among patients administered first-line atezolizumab plus carboplatin and etoposide for small cell lung cancer.

Wasamoto S, Imai H, Tsuda T, Nagai Y, Minemura H, Yamada Y, Umeda Y, Kishikawa T, Shiono A, Kozu Y, Shiihara J, Yamaguchi O, Mouri A, Kaira K, Kanazawa K, Taniguchi H, Kaburagi T, Minato K, Kagamu H

Frontiers in oncology 12 1080729 2022（ ISSN:2234-943X ）

Clinical Outcomes of Postoperative Adjuvant Chemotherapy for Surgically Resected High-Grade Pulmonary Neuroendocrine Carcinoma.

Kotake M, Imai H, Kaira K, Endoh H, Yamada Y, Kaburagi T, Kiyoshima M, Sugiyama T, Nakamura Y, Kasai T, Matsuguma H, Minemura H, Kanazawa K, Suzuki H, Fujita A, Minato K

Chemotherapy 67 ( 3 ) 142 - 151 2022（ ISSN:0009-3157 ）

Pretreatment glasgow prognostic score predicts survival among patients administered first-line atezolizumab plus carboplatin and etoposide for small cell lung cancer.

Wasamoto S, Imai H, Tsuda T, Nagai Y, Minemura H, Yamada Y, Umeda Y, Kishikawa T, Shiono A, Kozu Y, Shiihara J, Yamaguchi O, Mouri A, Kaira K, Kanazawa K, Taniguchi H, Kaburagi T, Minato K, Kagamu H

Frontiers in oncology 12 1080729 2022（ ISSN:2234-943X ）

Clinical Outcomes of Postoperative Adjuvant Chemotherapy for Surgically Resected High-Grade Pulmonary Neuroendocrine Carcinoma.

Kotake M, Imai H, Kaira K, Endoh H, Yamada Y, Kaburagi T, Kiyoshima M, Sugiyama T, Nakamura Y, Kasai T, Matsuguma H, Minemura H, Kanazawa K, Suzuki H, Fujita A, Minato K

Chemotherapy 67 ( 3 ) 142 - 151 2022（ ISSN:0009-3157 ）

Pretreatment glasgow prognostic score predicts survival among patients administered first-line atezolizumab plus carboplatin and etoposide for small cell lung cancer.

Wasamoto S, Imai H, Tsuda T, Nagai Y, Minemura H, Yamada Y, Umeda Y, Kishikawa T, Shiono A, Kozu Y, Shiihara J, Yamaguchi O, Mouri A, Kaira K, Kanazawa K, Taniguchi H, Kaburagi T, Minato K, Kagamu H

Frontiers in oncology 12 1080729 2022（ ISSN:2234-943X ）

Clinical Outcomes of Postoperative Adjuvant Chemotherapy for Surgically Resected High-Grade Pulmonary Neuroendocrine Carcinoma.

Kotake M, Imai H, Kaira K, Endoh H, Yamada Y, Kaburagi T, Kiyoshima M, Sugiyama T, Nakamura Y, Kasai T, Matsuguma H, Minemura H, Kanazawa K, Suzuki H, Fujita A, Minato K

Chemotherapy 67 ( 3 ) 142 - 151 2022（ ISSN:0009-3157 ）

Pretreatment glasgow prognostic score predicts survival among patients administered first-line atezolizumab plus carboplatin and etoposide for small cell lung cancer.

Wasamoto S, Imai H, Tsuda T, Nagai Y, Minemura H, Yamada Y, Umeda Y, Kishikawa T, Shiono A, Kozu Y, Shiihara J, Yamaguchi O, Mouri A, Kaira K, Kanazawa K, Taniguchi H, Kaburagi T, Minato K, Kagamu H

Frontiers in oncology 12 1080729 2022（ ISSN:2234-943X ）

Clinical Outcomes of Postoperative Adjuvant Chemotherapy for Surgically Resected High-Grade Pulmonary Neuroendocrine Carcinoma.

Kotake M, Imai H, Kaira K, Endoh H, Yamada Y, Kaburagi T, Kiyoshima M, Sugiyama T, Nakamura Y, Kasai T, Matsuguma H, Minemura H, Kanazawa K, Suzuki H, Fujita A, Minato K

Chemotherapy 67 ( 3 ) 142 - 151 2022（ ISSN:0009-3157 ）

Pretreatment Glasgow prognostic score predicts survival among patients with high PD-L1 expression administered first-line pembrolizumab monotherapy for non-small cell lung cancer.